Open Label Extension Study With Pramipexole (PPX) in Children With Tourette Syndrome.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pramipexole (Primary)
Indications Gilles de la Tourette's syndrome
Focus Adverse reactions; Registrational
Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

22 May 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
14 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-000342-32).
14 Apr 2012 Planned number of patients changed from 116 to 120 as reported by European Clinical Trials Database.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight